Methylprednisolone versus dexamethasone for brain swelling during radiotherapy for brain metastases
Compares methylprednisolone and dexamethasone for swelling around brain metastases in people having radiotherapy.
Key facts
- Who runs it
- The Second Affiliated Hospital of Hainan Medical University
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- Comparison of the Therapeutic Effects of Methylprednisolone and Dexamethasone on Peritumoral Edema During Radiotherapy for Brain Metastases:
- Status
- Not yet recruiting
- Phase
- Phase 2/3
- People taking part
- 400 people, planned
- Started
- 15 Apr 2026
- Expected to end
- 30 Jun 2028
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Methylprednisolone (Corticosteroid)
- Dexamethasone
- Record updated
- 21 April 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with cancer that has spread to the brain, with swelling around it. They must be planned for brain radiotherapy. The trial compares two steroid drugs, methylprednisolone and dexamethasone.
- Age
- 18 to 75 years
- Sex
- All sexes
- Disease stage
- At least one brain metastasis with brain swelling or nerve symptoms, seen on MRI or CT. KPS score (a daily-function score) of 40 to 80, limited mainly by symptoms from the swelling. Planned whole brain radiotherapy (30 Gy/10f or 20 Gy/5f) or stereotactic radiotherapy (20-40 Gy/1-6f, ≤ 5 brain metastases, each ≤ 5cm (2 in)). Stable symptoms with no need for emergency surgery. Expected survival of ≥ 3 months.
- Earlier treatment
- No systemic steroid treatment within 7 days before the study drug. Any earlier brain surgery or radiotherapy must be at least 4 weeks ago. No other treatment trial in the past 4 weeks.
- Biomarker or test result
- In people with diabetes, HbA1c ≤ 8.0% (64 mmol/mol). If higher, a hormone specialist must check and give written permission.
Main reasons for not taking part
- Need for immediate surgery to relieve brain pressure, or life-threatening brain pressure
- Cannot take steroids, or severely weakened immune system
- Serious illness such as uncontrolled high blood pressure or diabetes, active stomach ulcer, or heart failure (NYHA III-IV)
- Pregnant or breastfeeding women
- Severe memory or behaviour problems, or unable to attend follow-up
The registry criteria, word for word
Show all 2 criteriaShow less
Who can take part
- 1. 18 ≤ age ≤ 75 years old, gender not limited, generally acceptable, 40 ≤ KPS ≤ 80 points, the main reason for the patient's limited functional status is related neurological symptoms caused by edema of brain metastases; 2. Confirmed by cranial MRI or CT imaging, there is at least one brain metastasis with cerebral edema or neurological symptoms. All patients are scheduled to undergo WBRT (30 Gy/10f or 20 Gy/5f) or SBRT (20-40 Gy/1-6f, with ≤ 5 brain metastases and a maximum diameter of ≤ 5cm per lesion); 3. Expected survival of ≥ 3 months; 4. Having sufficient cognitive and understanding abilities, able to cooperate with scale assessments, and able to sign a written informed consent form (ICF); 5. Baseline neurological symptoms are stable (no need for emergency surgical decompression), and if surgery/radiotherapy has been performed, the following conditions must be met: postoperative/radiotherapy interval ≥ 4 weeks; 6. Baseline blood glucose/metabolism is controllable (e.g., HbA1c ≤ 8.0% in diabetes patients;If HbA1c is high, endocrinology evaluation is required and written permission for enrollment is granted
Who cannot take part
- 1. Immediate surgical decompression is required, or there may be progressive cerebral herniation, intracranial pressure crisis, or life-threatening intracranial space occupying lesions present; 2. Has received systemic corticosteroid treatment within 7 days prior to the start of the study medication (such as due to the treatment of systemic lupus erythematosus, bronchial asthma, etc.); 3. Recent cranial surgery or radiation therapy (<4 weeks); 4. Individuals with contraindications to glucocorticoids or severe immunosuppression; 5. Suffering from serious basic diseases such as uncontrolled hypertension and diabetes (HbA1c>8%), untreated mental illness, active gastric ulcer, heart failure (NYHA III-IV grade), etc; 6. Pregnant/lactating women; 7. Unable to complete the primary assessment scale (severe cognitive/behavioral impairment) or unable to sustain Follow up period (e.g. no fixed address, difficult to ensure follow-up); 8. Participated in other intervention therapy trials within the past 4 weeks (which may affect the evaluation results), or is currently receiving drugs that may have serious drug interactions with the investigational drug; 9. Other serious systemic diseases or unsuitability
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This study is a multicenter, open label, randomized controlled, adaptive phase II/III seamless design clinical trial aimed at comparing the efficacy and safety of methylprednisolone (MP) and dexamethasone (DEX) in the treatment of peritumoral edema in patients with brain metastases during radiotherapy. The research plan includes brain metastasis patients aged 18-75 years, with KPS scores of 40-80, who plan to undergo whole brain radiotherapy or stereotactic radiotherapy. They will be randomly divided into MP group (40-60 mg/day) or DEX group (8-12 mg/day) in a 1:1 ratio, and medication will be continued until the end of radiotherapy, followed by gradual reduction and cessation within one week. The study is divided into two stages: the first stage (stage II exploration) includes 120 cases to preliminarily evaluate the efficacy and safety, and provide a basis for re estimating the sample size in the second stage; The second stage (Phase III confirmation) will expand the sample size based on the results after analysis during the transition period, with a total sample size of no more than 400 cases. The primary endpoint was the change in KPS score and the incidence of grade ≥ 2 hormone related adverse reactions within one week after radiotherapy. Secondary endpoints include cerebral edema index, cognitive function, quality of life, radiotherapy interruption rate, neurotoxicity, survival, and serum biomarkers (IL-6, S100B). The study is supervised by an independent data security monitoring committee and uses statistical methods such as stratified block randomization and mixed effects models to ensure the scientific and ethical compliance of the data. This study is expected to provide high-level evidence-based basis for hormone selection during the perioperative radiotherapy period for patients with brain metastases, and optimize clinical practice.
The 2 groups in the trial
- Treatment group(Methylprednisolone)Treatment being tested
Methylprednisolone group regimen: The total daily dose is 40-60 mg (oral or intravenous), starting from the diagnosis of brain metastasis and continuing until the end of radiotherapy. Subsequently, the dosage is gradually reduced by 20-50% of the total dose, and complete discontinuation is achieved within one week.
Treatment: Methylprednisolone (Corticosteroid)
- Control group(Dexamethasone)Existing treatment, for comparison
The dosing regimen for the dexamethasone group is: a total daily dose of 8-12 mg (oral or intravenous), starting from the diagnosis of brain metastasis and continuing until the end of radiotherapy. Subsequently, the dosage is gradually reduced by 20-50% of the total dose, and complete discontinuation is achieved within one week.
Treatment: Dexamethasone
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Comparison of the Therapeutic Effects of Methylprednisolone and Dexamethasone on Peritumoral Edema During Radiotherapy for Brain Metastases:An Adaptive Phase II/III Seamless Prospective Clinical Study
- Plain-language title
- Methylprednisolone versus dexamethasone for brain swelling during radiotherapy for brain metastasesGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Criteria questions
- Built from NCT07542288, who can take part
- Record updated
- 21 April 2026